Editorial Staff

  • Executive Editor/VP-Special Projects:
    Jeff Hall
  • Senior Editor
    Brian McCurdy
  • Circulation and Subscriptions
    Bonnie Shannon
  • Art Director:
    Alana Balboni
  • Editorial Correspondence

  • Jeff Hall, Executive Editor/VP-Special Projects, Podiatry Today
  • HMP Communications, 83 General Warren Blvd
    Suite 100, Malvern PA 19355
  • Telephone: (800) 237-7285, ext. 214
    Fax: (610) 560-0501
  • Email: jhall@hmpcommunications.com
  • August 2003 | Volume 16 - Issue 8
    By Neal M. Blitz, DPM, and Ronald G. Ray, DPM, PT
    29,107 reads | 0 comments | 08/03/03
    The lapidus arthrodesis for the treatment of symptomatic hallux valgus remains a controversial subject in foot surgery. Since its inception in the early 1900s, the lapidus arthrodesis has been abandoned by many surgeons mainly due to its high complication rate, particularly nonunion. However, it has regained popularity in recent years due to better fixation techniques and an improved understanding of first ray biomechanics. The major advantage of performing a metatarsocuneiform arthrodesis is it allows you to realign the first metatarsal at the apex of the deformity along with stabilizing th ... continue reading

    2,308 reads | 0 comments | 08/03/03
    Who isn’t always on the lookout for new devices to make reimbursement less of a hassle? In order to make the process a little easier, you may want to consider the Smartdop® 20EX with Smart-V-Link™ Vascular Software. The product features Smart-V-Link Vascular Software and is complete with ABI and TBI software. It reportedly helps facilitate easier documentation of preoperative procedures for the patient’s record and for reimbursement purposes as well, according to the company Koven Technology. It adds that the software can also automatically calculate ratios and print ... continue reading
    By John Mozena, DPM
    17,648 reads | 0 comments | 08/03/03
    Onychomycosis is the number one diagnosed and treated disease by podiatrists today. While the disease was first recognized in the United States in 1928, it has only recently been brought under control with drugs that have been introduced in the last 10 years. With the advent of safer oral and topical medications, there has been a renewed focus on increasing efficacy rates. The current research seems to be centered on synergistic activity of oral and topical medications as well as different vehicles to add additional penetration of the medication. Onychomycosis is present in 2 to 3 percent ... continue reading